AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in conjunction with metronidazole for people aged 18 and over with complicated ...

AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections, including those caused by drug-resistant bacteria.

So, on February 7, 2025, the FDA approved Emblaveo in combination with metronidazole ... Dear Seeking Alpha readers, let's continue to delve into AbbVie's latest achievements and failures with ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI), including those caused by Gram-negative bacteria that represent a ...

The healthcare sector, too, has seen advances with AbbVie's EMBLAVEO™ gaining FDA approval for a combination antibiotic, and the European Medicines Agency recommending its arthritis treatment ...

AbbVie is navigating significant shareholder ... This collaborative approach, alongside the FDA approval of innovative products like EMBLAVEO, has reinforced investor confidence.

AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative ...

AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of ...